Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier

Current Nanoscience

Volumn 7, Issue 4, 2011, Pages 524-530

  Jain, Sanyog ^a   Mittal, Ankit ^a   Jain, Amit K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Clsm; Cyclosporin a; Plga nanoparticles; Skin permeation; Topical delivery

Indexed keywords

CLSM; CYCLOSPORIN A; PLGA NANOPARTICLES; SKIN PERMEATION; TOPICAL DELIVERY;

EMULSIFICATION; POLYDISPERSITY; TOXICITY;

NANOPARTICLES;

CYCLOSPORIN A; NANOCARRIER; POLYGLACTIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED STUDY; DIFFUSION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; EVAPORATION; HISTOLOGY; IN VITRO STUDY; MEASUREMENT; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SKIN; SKIN PENETRATION;

RATTUS;

EID: 79959959337     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341311796196835     Document Type: Article

References (38)

1. Berth-Jones, J. The use of ciclosporin in psoriasis. J. Dermatol. Treat., 2005, 16(5), 258-277.
2. Choi, H.K.; Flynn, G.L.; Amidon, G.L. Percutaneous absorption and dermal delivery of cyclosporin A. J. Pharm. Sci., 1995, 84(5), 581-583.
3. Duncan, J.I.; Wakeel, R.A.; Winfield, A.J.; Ormerod, A.D.; Thomson, A.W. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta. Derm. Venereol., 1993, 73(2), 84-87.
4. Wang, S.; Kara, M.; Krishnan, T.R.; Transdermal delivery of cyclosporin-A using electroporation. J. Control. Release, 1998, 50(1-3), 61-70.
5. Boinpally, R.R.; Zhou, S.-L.; Devraj, G.; Anne, P.K.; Poondru, S.; Jasti, B.R. Iontophoresis of lecithin vesicles of cyclosporin A. Int. J. Pharm., 2004, 274(1-2), 185-190.
6. Liu, H.; Li, S.; Pan, W.; Wang, Y.; Han, F.; Yao, H. Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A. Int. J. Pharm., 2006, 326(1-2), 32-38.
7. Gajardo, J.; Villaseca, J. Psoriasis and cyclosporine: an attempt at topical treatment. Rev. Med. Chil., 1994, 122(12), 1404-1407.
8. Shim, J.; Seok, K.H.; Park, W.S.; Han, S.H.; Kim, J.; Chang, I.S. Transdermal delivery of minoxidil with block copolymer nanoparticles. J. Control. Release, 2004, 97(3), 477-484.
9. Benson, H.A.E.; Namjoshi, S. Proteins and peptides: Strategies for delivery to and across the skin. J. Pharm. Sci., 2008, 97(9), 3591-3610.
10. Chen, H.; Chang, X.; Du, D.; Liu, W.; Liu, J.; Weng, T.; Yang, Y.; Xu, H.; Yang, X. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Release, 2006, 110(2), 296-306.
11. Jenning, V.; Schäfer-Korting, M.; Gohla, S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Release, 2000, 66(2-3), 115-126.
12. Müller, R.H.; Petersen, R.D.; Hommoss, A.; Pardeike, J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug. Deliv. Rev., 2007, 59(6), 522-530.
13. Sivaramakrishnan, R.; Nakamura, C.; Mehnert, W.; Korting, H.C.; Kramer, K.D.; Schäfer-Korting, M. Glucocorticoid entrapment into lipid carrierscharacterisation by parelectric spectroscopy and influence on dermal uptake. J. Control. Release, 2004, 97(3), 493-502.
14. Souto, E.B.; Wissing, S.A.; Barbosa, C.M.; Müller, R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm., 2004, 278(1), 71-77.
15. de Jalón, E.G.; Blanco-Príeto, M.J.; Ygartua, P.; Santoyo, S. PLGA microparticles: possible vehicles for topical drug delivery. Int. J. Pharm., 2001, 226(1-2), 181-184.
16. Luengo, J.; Weiss, B.; Schneider, M.; Ehlers, A.; Stracke, F.; Konig, K.; Kostka, K.H.; Lehr, C.M.; Schaeferb, U.F. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin. Pharmacol. Physiol., 2006, 19(4), 190-197.
17. Alvarez-Roman, R.; Naik, A.; Kalia, Y.N.; Guy, R.H.; Fessi, H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm. Res., 2004, 21(10), 1818-1825.
18. Hariharan, S.; Bhardwaj, V.; Bala, I.; Sitterberg, J.; Bakowsky, U.; Ravi Kumar, M.N. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm. Res, 2006, 23(1), 184-195.
19. Jain, S.; Mittal, A.; Jain, A. K.; Mahajan, R.; Singh, D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Curr. Nanosci., 2010, 6(4), 422-431.
20. Italia, J.L.; Bhatt, D.K.; Bhardwaj, V.; Tikoo, K.; Kumar, M.N.V.R. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J. Control. Release, 2007, 119(2), 197-206.
21. Panchagnula, R.; Bokalial, R.; Sharma, P.; Khandavilli, S. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies. Int. J. Pharm., 2005, 293(1-2), 213-223.
22. Guo, J.; Ping, Q.; Sun, G.; Jiao, C. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int. J. Pharm., 2000, 194(2), 201-207.
23. Lopes, L.B.; Ferreira, D.A.; de Paula, D.; Garcia, M.T.; Thomazini, J.A.; Fantini, M.C.A.; Bentley, M.V.L.B. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm. Res., 2006, 23(6), 1332-1342.
24. Wang, D.P.; Lin, C.Y.; Chu, D.L.; Chang, L.C. Effect of various physical/ chemical properties on the transdermal delivery of cyclosporin through topical application. Drug. Dev. Ind. Pharm., 1997, 23(1), 99-106.
25. Lopes, L.B.; Collett, J.H.; Bentley, M.V.L.B. Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur. J. Pharm. Biopharm., 2005, 60(1), 25-30.
26. Escobar-Chavez, J.J.; Merino-Sanjuan, V.; Lopez-Cervantes, M.; Urban- Morlan, Z.; Pinon-Segundo, E.; Quintanar-Guerrero, D.; Quintanar, G. The tape-stripping technique as a method for drug quantification in skin. J. Pharm. Pharm. Sci., 2008, 11(1), 104-130.
27. Lashmar, U.T.; Hadgraft, J.; Thomas, N. Topical application of penetration enhancers to the skin surface of nude mice: a histopathological study. J. Pharm. Pharmacol., 1989, 41(1), 118-122.
28. du Plessis, J.; Egbaria, K.; Ramachandran, C.; Weiner, N. Topical delivery of liposomally encapsulated gamma-interferon. Antiviral. Res., 1992, 18(3-4), 259-265.
29. Rolland, A.; Wagner, N.; Chatelus, A.; Shroot, B.; Schaefer, H. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm. Res., 1993, 10(12), 1738-1744.
30. Sheihet, L.; Chandra, P.; Batheja, P.; Devore, D.; Kohn, J.; Michniak, B. Tyrosine-derived nanospheres for enhanced topical skin penetration. Int. J. Pharm., 2008, 350(1-2), 312-319.
31. Barry, B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci., 2001, 14(2), 101-114.
32. Knorr, F.; Lademann, J.; Patzelt, A.; Sterry, W.; Blume-Peytavi, U.; Vogt, A. Follicular transport route--research progress and future perspectives. Eur. J. Pharm. Biopharm., 2009, 71(2), 173-180.
33. Scheuplein, R.J. Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration. J. Invest. Dermatol., 1967, 48(1), 79-88.
34. Ogiso, T.; Shiraki, T.; Okajima, K.; Tanino, T.; Iwaki, M.; Wada, T. Transfollicular drug delivery: penetration of drugs through human scalp skin and comparison of penetration between scalp and abdominal skins in vitro. J. Drug. Target., 2002, 10(5), 369-378.
35. Bodemer, C.; Peuchmaur, M.; Fraitaig, S.; Chatenoud, L.; Brousse, N.; De. P.Y. Role of cytotoxic T cells in chronic alopecia areata. J. Invest. Dermatol., 2000, 114, 112-116.
36. Verma, D.D.; Verma, S.; McElwee, K.J.; Freyschmidt-Paul P.; Hoffman, R.; Fahr, A. Treatment of alopecia areata in the DEBR model using Cyclosporin A lipid vesicles. Eur. J. Dermatol., 2004, 14(5), 332-338.
37. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70(1-2), 1-20.
38. Baker, B.S.; Fry, L. Immunotargeting: A biological approach to the treatment of psoriasis. DDT: Ther. Strategies., 2007, 4(3), 201-207.